Filing Details

Accession Number:
0001127602-24-007949
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-01 17:33:25
Reporting Period:
2024-02-28
Accepted Time:
2024-03-01 17:33:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1682852 Moderna Inc. MRNA Biological Products, (No Disgnostic Substances) (2836) 813467528
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1736359 M James Mock 200 Technology Square
Suite 300
Cambridge MA 02139
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-28 1,315 $0.00 4,947 No 4 M Direct
Common Stock Disposition 2024-02-29 647 $94.57 4,300 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-02-28 1,315 $0.00 1,315 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,945 No 4 M Direct
Footnotes
  1. Restricted stock units convert into common stock on a one-for-one basis.
  2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  3. 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.